Background: Psoriasis patients are believed to be at an increased risk of cardiovascular (CV) morbidity, and the effect of biological agents on CV safety is not fully understood.
Objective: To evaluate the effect of ustekinumab on CV events using detailed analyses of pooled data from the phase II/III clinical studies of its use in moderate-to-severe psoriasis.
Methods: The incidence of major adverse CV events (MACE; myocardial infarction [MI], stroke, or CV death) is reported. Meta-analyses using risk difference and odds ratio (OR) estimates are presented based on data collected during the placebo-controlled ...
Cardiovascular safety of ustekinumab in patients with moderate-to-severe psoriasis: Results of integrated analyses of data from phase II and III clinical studies is a post from: Skincare
Cardiovascular safety of ustekinumab in patients with moderate-to-severe psoriasis: Results of integrated analyses of data from phase II and III clinical studies via BuzzBlazer.com
No comments:
Post a Comment